Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A person who has signed a consent form agreeing to take part in the study.
• A person whose previous cancer treatments ended at least 21 days ago (or a shorter period based on the specific drug used), and whose side effects from those treatments have mostly resolved.
• A person who has at least one area of cancer that can be seen and measured on a scan, and that can be checked again over time.
• A person whose blood counts, kidney function, liver function, and blood clotting results are within an acceptable range without needing transfusions or growth factor support.
• A person who has a tumour tissue sample available (either stored from a previous biopsy or from a new biopsy) that can be sent for testing.
• A person who is willing and able to use highly effective contraception plus a barrier method during the study and for a period after the last dose (the exact timeframe depends on which treatments are received and whether the person can become pregnant or father a child).
• A person who is expected to live for at least 12 weeks.
• A person who is willing to attend all required study visits and follow the study procedures.
• A person whose general physical condition is rated 0 or 1 on the ECOG performance scale, meaning they are fully active or restricted in strenuous activity but able to carry out light work (confirm with trial site if unsure what this means for a specific situation).
• A person with certain gene changes (such as ATM gene alterations, BRCA mutations, or HRD-positive cancer) depending on which part of the trial they are being considered for (confirm specific requirements with the trial site).
• For some parts of the trial, a person whose cancer is advanced or has spread and has not responded to standard treatments, or for whom no standard treatments exist.
• For some parts of the trial, a person with a specific cancer type, such as high-grade serous ovarian, fallopian tube or peritoneal cancer; endometrial cancer; colorectal cancer; or pancreatic cancer — each with additional specific requirements (confirm details with the trial site).
• For some parts of the trial, a person who has previously received certain treatments (such as platinum-based chemotherapy, taxane chemotherapy, PARP inhibitors, or PD-1/PD-L1 inhibitors) where those treatments are approved and available for their cancer type, unless those treatments were not suitable for them.

Who may not be able to join:

• A person who is pregnant, breastfeeding, or planning to become pregnant during the study or within 7 months after the last dose of study treatment.
• A person who plans to father a child during the study or within 5 months after the last dose.
• A person with a serious ongoing illness that would make it difficult to follow the study requirements, including active HIV-related infections in the past 12 months, active hepatitis B or C, active tuberculosis, or another cancer that is not currently in remission.
• A person who has ongoing lung inflammation (interstitial lung disease or pneumonitis), whether or not it is causing symptoms.
• A person with moderate or severe heart or cardiovascular disease.
• A person with significant heart valve problems.
• A person with significant abnormalities on a heart tracing (ECG) that are considered clinically important.
• A person with brain metastases, spinal cord compression, or cancer affecting the lining of the brain or spinal cord that is causing symptoms or is not well controlled, and that requires ongoing treatment.
• A person who received a live vaccine within 30 days before the first dose of study treatment.
• A person who has any other condition, previous treatment, or test result that could interfere with the study results or make participation not in their best interest (confirm with trial site).
• A person who had major surgery within 4 weeks before joining the study, or minor surgery within 1 week before joining.
• A person who had fluid drained from around their abdomen, lungs, or heart within 4 weeks before the first dose.
• A person with a significant bleeding disorder or who had a serious bleeding episode within 12 weeks before joining.
• A person who is already taking part in another clinical trial involving an investigational treatment.
• For parts of the trial involving irinotecan: a person with a specific inherited difference in how their body processes irinotecan (related to the UGT1A1 gene — confirm with trial site), or a person taking certain medications that affect this process within 2 weeks before the first dose.
• For the pancreatic cancer part of the trial (Part B6): a person with a neuroendocrine or adenosquamous type of pancreatic cancer.

Important: Always verify eligibility with the trial site directly before applying.